|
Case Abstract
Pfizer paid $85,000,000 to a class of consumers and health benefit plan providers (“TPPs”) to settle claims of allegedly fraudulent marketing of the Cox-2 inhibitor painkillers Bextra and Celebrex. Bextra was withdrawn from the market by Pfizer due to its risks of heart attacks and strokes. Lowey Dannenberg represented the interests of TPP members of the settlement class with respect to allocation of settlement proceeds between TPPs and consumers in negotiations resulting in the allocation of $59,000,000 of the settlement award to TPPs.
Richard Cohen was the Lowey Dannenberg lawyer responsible.
Clients
The health benefit plan providers within the settlement class.
Case Name
In re Bextra and Celebrex Marketing, Sales Practices, and Product Liability Litigation, No. 05-cv-01699 (N.D. Calif.) (United States District Judge Charles R. Breyer).
Current Status
Settled.
|
Content Management System (CMS)